Day: March 24, 2022

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2021 financial results and summarized recent program developments. Recent Program Developments and Highlights Validive – International Phase 2b/3 VOICE Clinical Trial, Actively RecruitingValidive is a novel mucobuccal tablet formulation for clonidine that has been designed to provide for prolonged and enhanced local delivery...

Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study for Autism Spectrum Disorder in First Half of 2022 Recent $100 million Royalty and Debt agreement provides a projected cash runway into 2024 Impel To Host Investor Conference Call Today At 8:30 A.M. ET SEATTLE, March 24, 2022 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update. “We are pleased to see that our targeted and...

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “Surrozen’s significant achievements in 2021 have prepared us to transition to a clinical-stage biotechnology company as we drive toward multiple key milestones in 2022,” said Craig Parker, President and Chief Executive Officer of Surrozen. “We are on track to advance our lead therapeutic candidates, SZN-1326 and SZN-043, into the clinic in the...

Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol® MIRA-3 Phase 3 Results Expected End of 1Q 2022– MIRA-4 Pediatric, and LYNX-1 Phase 3 Results Expected to follow in 2Q 2022– ZETA-1 Phase 2 Diabetic Retinopathy Results Expected in 2H 2022 NDA Filing for Nyxol in Reversal of Mydriasis Planned for Late 2022 with Potential Launch as First Dilation Reversal Drop in 2H 2023 Plans to Initiate VEGA Phase 3 FDA Registration Trials for Nyxol Alone and in Combination with Low-Dose Pilocarpine (LDP) in Presbyopia in Mid-2022 FARMINGTON HILLS, Mich., March 24, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of...

Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022 YONKERS, N.Y., March 24, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the fourth quarter and full year ended December 31, 2021. “Most importantly, we are on track and continue to expect to conduct the planned interim futility analysis based on approximately 60% of the MRSA study population by the end of the first half of 2022. Unlike other analyses for non-inferiority, this analysis...

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company’s lead program into clinical trials —Compelling preclinical data presented on lead program GBA1 Parkinson’s Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end — Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications  BETHESDA, Md., March 24, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced its financial results for...

Fourth Quarter Net Revenues Grew More than 80%; Fiscal Year 2021 Net Revenues up Nearly 100% Opened 353 Net New Stores in Fourth Quarter; One of The Largest Coffee Networks in China with More than 6,000 Stores Achieved 20.9% Store Level Profit for Self-Operated Stores in Fourth Quarter Successful Conclusion of Provisional Liquidation BEIJING, March 24, 2022 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended December 31, 2021 and fiscal year 2021. COMPANY STATEMENT “We are very pleased to report strong overall performance in the fourth quarter and fiscal year 2021,” said Dr. Jinyi Guo, Chairman and Chief Executive Officer of Luckin Coffee. “We opened more than 350 net new stores during the quarter and are one of the largest...